Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation
- PMID: 19861311
- DOI: 10.1093/ndt/gfp552
Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation
Abstract
Cell therapies aim at differentiation of stem cells into the specific cell type required to repair damaged or destroyed cells or tissues. Over recent years, cell therapy has been introduced in a variety of application areas, including cardiovascular repair, diabetes, musculoskeletal disorders and renal repair. Multipotent mesenchymal stromal cells (MSCs), often referred to as mesenchymal stem cells, are of particular interest as a cell therapy model, as this is one of the few cell types that are on the brink of entering the clinical arena in different areas of application. MSCs can be differentiated in vitro and in vivo into various cell types of mesenchymal origin such as bone, fat and cartilage. They have important effects on the innate and adaptive immune system and possess striking anti-inflammatory properties that make them attractive for potential use in diseases characterized by autoimmunity and inflammation. In addition, MSCs have been shown to migrate to sites of tissue injury and to enhance repair by secreting anti-fibrotic and pro-angiogenic factors. In this review, evidence for the renoprotective mechanisms of MSCs as well as their therapeutic possibilities and potential hazards in acute and chronic renal disease and allograft rejection is summarized.
Similar articles
-
Mesenchymal stromal cells.Ann N Y Acad Sci. 2009 Sep;1176:101-17. doi: 10.1111/j.1749-6632.2009.04607.x. Ann N Y Acad Sci. 2009. PMID: 19796238 Review.
-
Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice.Biol Blood Marrow Transplant. 2008 Jun;14(6):631-40. doi: 10.1016/j.bbmt.2008.01.006. Epub 2008 Apr 14. Biol Blood Marrow Transplant. 2008. PMID: 18489988
-
Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?Rheumatology (Oxford). 2009 Oct;48(10):1185-9. doi: 10.1093/rheumatology/kep162. Epub 2009 Jun 26. Rheumatology (Oxford). 2009. PMID: 19561159 Review.
-
Multipotent mesenchymal stromal cells attenuate chronic inflammation and injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury.Restor Neurol Neurosci. 2009;27(4):307-21. doi: 10.3233/RNN-2009-0480. Restor Neurol Neurosci. 2009. PMID: 19738324
-
Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks.Bone Marrow Transplant. 2009 Jun;43(11):821-8. doi: 10.1038/bmt.2009.63. Epub 2009 Mar 23. Bone Marrow Transplant. 2009. PMID: 19308035 Review.
Cited by
-
Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth.PLoS One. 2010 Sep 23;5(9):e12920. doi: 10.1371/journal.pone.0012920. PLoS One. 2010. PMID: 20886110 Free PMC article.
-
Impact of Mesenchymal Stromal Cells and Their Extracellular Vesicles in a Rat Model of Kidney Rejection.Front Cell Dev Biol. 2020 Jan 29;8:10. doi: 10.3389/fcell.2020.00010. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32064259 Free PMC article.
-
Delivery of Mesenchymal Stem Cells during Hypothermic Machine Perfusion in a Translational Kidney Perfusion Study.Int J Mol Sci. 2024 May 5;25(9):5038. doi: 10.3390/ijms25095038. Int J Mol Sci. 2024. PMID: 38732257 Free PMC article.
-
Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies.Stem Cell Res Ther. 2013 Apr 30;4(2):48. doi: 10.1186/scrt198. Stem Cell Res Ther. 2013. PMID: 23632128 Free PMC article.
-
Autologous omentum transposition for regeneration of a renal injury model in rats.Mil Med Res. 2022 Jan 4;9(1):1. doi: 10.1186/s40779-021-00361-0. Mil Med Res. 2022. PMID: 34983664 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical